Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

Richard B. Warren; April W. Armstrong; Melinda Gooderham; Bruce Strober; Diamant Thaçi; Shinichi Imafuku; Howard Sofen; Lynda Spelman; Neil J. Korman; Min Zheng; Elizabeth Colston; John Throup; Sudeep Kundu; Renata M. Kisa; Subhashis Banerjee; Andrew Blauvelt

doi:10.25251/skin.6.supp.4

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

Richard B. Warren^*, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil J. Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt

^*Corresponding author for this work

Institute of Inflammation Medicine

3 Citations (Scopus)

Original language	English
Journal	SKIN: Journal of Cutaneous Medicine
Volume	6
Issue number	2
DOIs	https://doi.org/10.25251/skin.6.supp.4
Publication status	Published - 2022

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

205-19 Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.25251/skin.6.supp.4

Cite this

Warren, R. B., Armstrong, A. W., Gooderham, M., Strober, B., Thaçi, D., Imafuku, S., Sofen, H., Spelman, L., Korman, N. J., Zheng, M., Colston, E., Throup, J., Kundu, S., Kisa, R. M., Banerjee, S., & Blauvelt, A. (2022). Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN: Journal of Cutaneous Medicine, 6(2). https://doi.org/10.25251/skin.6.supp.4

@article{b83f396627b04e59bb2e3b7cb824f00f,

title = "Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials",

author = "Warren, {Richard B.} and Armstrong, {April W.} and Melinda Gooderham and Bruce Strober and Diamant Tha{\c c}i and Shinichi Imafuku and Howard Sofen and Lynda Spelman and Korman, {Neil J.} and Min Zheng and Elizabeth Colston and John Throup and Sudeep Kundu and Kisa, {Renata M.} and Subhashis Banerjee and Andrew Blauvelt",

year = "2022",

doi = "10.25251/skin.6.supp.4",

language = "English",

volume = "6",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

number = "2",

}

Warren, RB, Armstrong, AW, Gooderham, M, Strober, B, Thaçi, D, Imafuku, S, Sofen, H, Spelman, L, Korman, NJ, Zheng, M, Colston, E, Throup, J, Kundu, S, Kisa, RM, Banerjee, S & Blauvelt, A 2022, 'Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials', SKIN: Journal of Cutaneous Medicine, vol. 6, no. 2. https://doi.org/10.25251/skin.6.supp.4

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. / Warren, Richard B.; Armstrong, April W.; Gooderham, Melinda et al.
In: SKIN: Journal of Cutaneous Medicine, Vol. 6, No. 2, 2022.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis

T2 - 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

AU - Warren, Richard B.

AU - Armstrong, April W.

AU - Gooderham, Melinda

AU - Strober, Bruce

AU - Thaçi, Diamant

AU - Imafuku, Shinichi

AU - Sofen, Howard

AU - Spelman, Lynda

AU - Korman, Neil J.

AU - Zheng, Min

AU - Colston, Elizabeth

AU - Throup, John

AU - Kundu, Sudeep

AU - Kisa, Renata M.

AU - Banerjee, Subhashis

AU - Blauvelt, Andrew

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85143365223&partnerID=8YFLogxK

U2 - 10.25251/skin.6.supp.4

DO - 10.25251/skin.6.supp.4

M3 - Journal articles

AN - SCOPUS:85143365223

SN - 2574-1624

VL - 6

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Cite this